Bloomberg Businessweek Weekend - August 16th, 2024
Bloomberg Businessweek
00:00
The GLP-1 Drug Landscape: A Competitive Overview
This chapter examines the competitive dynamics of the GLP-1 diet drug market, spotlighting Eli Lilly and Novo Nordisk's contrasting performances. It highlights Eli Lilly's recent success and strategic advantages, while addressing Novo's challenges amidst rising pressure. The discussion also touches on the societal impacts of these drugs, particularly in Bowling Green, Kentucky, and personal stories of individuals navigating the complexities of weight-loss treatments.
Play episode from 35:21
Transcript
